Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Acute Repetitive Seizures Market

Acute Repetitive Seizures Market Trends

Report ID: GMI11873
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Acute Repetitive Seizures Market Trends

The rising prevalence of epilepsy and seizure disorders is a key driver of the ARS market.
According to the National Institute of Neurological Disorders and Stroke (NINDS), epilepsy affects people of all ages, with onset most common in children and older adults. Approximately 1 in 26 people will develop epilepsy at some point in their lifetime. The Epilepsy Foundation reports that about 30-40% of people with epilepsy continue to have seizures despite treatment. Among these, many experience seizure clusters or acute repetitive seizures.
The growing number of epilepsy patients directly increases the demand for treatments to manage associated complications, including seizure clusters (SC) or acute repetitive seizures (ARS), which are common among people with epilepsy (PWE).
As more epilepsy patients report experiencing seizure clusters, the demand for effective ARS treatments is rising, contributing to market growth.
Furthermore, the high prevalence of epilepsy has encouraged pharmaceutical companies to invest in developing user-friendly, fast-acting treatments. These include intranasal rescue medications and other therapies that offer non-invasive administration, driving market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for acute repetitive seizures was valued at USD 2.7 billion in 2023 and is expected to reach USD 7.7 billion by 2032, driven by a CAGR of 12.4% from 2024 to 2032, primarily due to the increasing prevalence of epilepsy and advancements in rescue therapies.

The intranasal segment was valued at USD 1.2 billion in 2023, driven by its non-invasive, convenient, and rapid drug delivery method essential for managing seizure emergencies.

The North America market was valued at USD 1.1 billion in 2023, driven by the high prevalence of epilepsy and a robust healthcare infrastructure that facilitates timely diagnosis and management.

Prominent players in the industry include AdvaCare Pharma Limited, Aquestive Therapeutics, Bausch Health Companies, Lupin Limited, Neuracle Lifesciences, Neurelis, and Pfizer, driven by their continuous development of novel rescue medications.